Volume 2, Issue 2
Patent expirations, cost-cutting initiatives and regulatory reform boost prospects for generics.
FDA is trying to determine if it is possible to approve a biogeneric in the absence of full trial data.
Process Analytical Technology could have big impact on suppliers and their customers.
